Daniel Howard Wiznia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Howard Wiznia has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Steven M. Tommasini
Yale University, New Haven, CT, USA
13 shared publications - Gregory Ronald Roytman
Department of Orthopaedics & Rehabilitation, Yale University, New Haven, CT, 06520, USA
10 shared publications Steven M. Tommasini
Orthopaedics and Rehabilitation Yale University New Haven Connecticut USA
9 shared publications- Kelsey A. Rankin
Yale School of Medicine
7 shared publications Chang-Yeon Kim
6 shared publicationsMichael P. Leslie
Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT, USA
6 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- 16 July 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Effectiveness of a Robotic Mirror Therapy Device Compared to Conventional Mirror Therapy for Hand Rehabilitation
Objective: This study aimed to evaluate the effectiveness in improving pain and motor function of a robotic mirror therapy device for hand rehabilitation that replicates the movement of fingers of the unaffected hand on the affected side. Design: In a preliminary clinical trial, participants with hemiparesis were randomized to (1) an intervention group receiving device-assisted training or (2) a control group receiving conventional mirror therapy. Both groups trained three times per week for 15 minutes until discharge from the inpatient rehabilitation unit after two to three weeks. Motor function, measured with the Jebsen-Taylor Hand Function Test, and pain, assessed with the short-form McGill Pain Questionnaire and Visual Analog Scale, were compared at first admission and at discharge. Results: Motor function improvements did not differ significantly between the two groups( P =0.423) after therapy ended, but comparing motor function scores before and after therapy within each group showed significant improvement only for the intervention group ( P =0.012) but not for the control group ( P =0.110). No meaningful improvement in pain was observed, as most patients reported being pain-free before and after therapy. Conclusion: Despite positive within-subject findings in the intervention group, superiority could not be fully concluded due to the limited sample size and missing between-group differences. A larger clinical trial is recommended to better assess effectiveness.
- 16 July 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Effectiveness of a Robotic Mirror Therapy Device Compared to Conventional Mirror Therapy for Hand Rehabilitation
Objective: This study aimed to evaluate the effectiveness in improving pain and motor function of a robotic mirror therapy device for hand rehabilitation that replicates the movement of fingers of the unaffected hand on the affected side. Design: In a preliminary clinical trial, participants with hemiparesis were randomized to (1) an intervention group receiving device-assisted training or (2) a control group receiving conventional mirror therapy. Both groups trained three times per week for 15 minutes until discharge from the inpatient rehabilitation unit after two to three weeks. Motor function, measured with the Jebsen-Taylor Hand Function Test, and pain, assessed with the short-form McGill Pain Questionnaire and Visual Analog Scale, were compared at first admission and at discharge. Results: Motor function improvements did not differ significantly between the two groups( P =0.423) after therapy ended, but comparing motor function scores before and after therapy within each group showed significant improvement only for the intervention group ( P =0.012) but not for the control group ( P =0.110). No meaningful improvement in pain was observed, as most patients reported being pain-free before and after therapy. Conclusion: Despite positive within-subject findings in the intervention group, superiority could not be fully concluded due to the limited sample size and missing between-group differences. A larger clinical trial is recommended to better assess effectiveness.
- Open Access
- 1 July 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 61, 640-656
Collagen II hydrogel-mediated sustained delivery of lacosamide attenuates cartilage degeneration and pain in osteoarthritis
Osteoarthritis (OA) lacks effective disease-modifying therapies. Nav1.7 has recently been identified as a regulator of both chondrocyte metabolism and pain, establishing it as a dual-acting therapeutic target in OA. This study evaluated lacosamide (LCM) as a disease-modifying candidate and developed a cartilage-targeted delivery strategy to enhance its translational potential. Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes, cartilage explants, and a murine DMM model with systemic or intra-articular administration. Pain behavior was assessed by von Frey and open-field testing. A collagen II–based thermoresponsive hydrogel was developed for sustained intra-articular delivery, and outcomes were assessed by histology, immunohistochemistry, ELISA, and gene expression analyses. LCM was the most potent inhibitor in suppressing IL-1β–induced catabolism and promoting anabolism in human chondrocytes, showing greater efficacy at lower concentrations than carbamazepine or oxcarbazepine. Systemic LCM reduced cartilage degeneration and pain in murine OA and outperformed carbamazepine at equivalent doses, while intra-articular administration achieved superior protection and analgesia at one-tenth the dose. Mechanistically, LCM increased HSP70 and midkine secretion to drive anabolic and anti-catabolic responses. Sustained delivery via a collagen II-based hydrogel prolonged joint retention and enhanced therapeutic durability. Together with its clinical efficacy in Nav1.7 mutation–related neuropathy, these findings underscore LCM's translational potential as a dual-acting disease-modifying therapy for OA. LCM is a dual-acting Nav1.7 inhibitor that alleviates pain and modifies OA progression. Collagen II–based intra-articular delivery enhances efficacy and supports clinical translation as a noninvasive, non-opioid disease-modifying therapy.
- 1 July 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 61, 640-656
Open AccessCollagen II hydrogel-mediated sustained delivery of lacosamide attenuates cartilage degeneration and pain in osteoarthritis
Osteoarthritis (OA) lacks effective disease-modifying therapies. Nav1.7 has recently been identified as a regulator of both chondrocyte metabolism and pain, establishing it as a dual-acting therapeutic target in OA. This study evaluated lacosamide (LCM) as a disease-modifying candidate and developed a cartilage-targeted delivery strategy to enhance its translational potential. Sodium channel inhibitors (carbamazepine, oxcarbazepine, and LCM) were evaluated in primary human OA chondrocytes, cartilage explants, and a murine DMM model with systemic or intra-articular administration. Pain behavior was assessed by von Frey and open-field testing. A collagen II–based thermoresponsive hydrogel was developed for sustained intra-articular delivery, and outcomes were assessed by histology, immunohistochemistry, ELISA, and gene expression analyses. LCM was the most potent inhibitor in suppressing IL-1β–induced catabolism and promoting anabolism in human chondrocytes, showing greater efficacy at lower concentrations than carbamazepine or oxcarbazepine. Systemic LCM reduced cartilage degeneration and pain in murine OA and outperformed carbamazepine at equivalent doses, while intra-articular administration achieved superior protection and analgesia at one-tenth the dose. Mechanistically, LCM increased HSP70 and midkine secretion to drive anabolic and anti-catabolic responses. Sustained delivery via a collagen II-based hydrogel prolonged joint retention and enhanced therapeutic durability. Together with its clinical efficacy in Nav1.7 mutation–related neuropathy, these findings underscore LCM's translational potential as a dual-acting disease-modifying therapy for OA. LCM is a dual-acting Nav1.7 inhibitor that alleviates pain and modifies OA progression. Collagen II–based intra-articular delivery enhances efficacy and supports clinical translation as a noninvasive, non-opioid disease-modifying therapy.
- Open Access
- 24 May 2026
- Published by Wiley in Arthroscopy Techniques
- Vol. 15 (8)
A Multiplanar Reformatting Technique to Correct for Scanner Misalignment During Computed Tomography Measurement of Tibial Tuberosity‐Trochlear Groove Distance
The tibial tuberosity‐trochlear groove distance (TT‐TG) is a commonly used measurement that impacts clinical decision making for patellofemoral instability. When measured using 2‐dimensional axial slices from imaging modalities like computed tomography (CT) scans, it has been shown to be prone to error depending on patient alignment with the scanner's longitudinal axis. In this technique article, we describe a method using multiplanar reformatting on 2‐dimensional CT scans to create an altered coordinate system to measure TT‐TG measurements more accurately and efficiently. This method can drastically impact the accuracy and reproducibility of TT‐TG measurements for misaligned scans and can help ensure that patients are treated appropriately for their individual level of dysplasia.
- 24 May 2026
- Published by Wiley in Arthroscopy Techniques
- Vol. 15 (8)
Open AccessA Multiplanar Reformatting Technique to Correct for Scanner Misalignment During Computed Tomography Measurement of Tibial Tuberosity‐Trochlear Groove Distance
The tibial tuberosity‐trochlear groove distance (TT‐TG) is a commonly used measurement that impacts clinical decision making for patellofemoral instability. When measured using 2‐dimensional axial slices from imaging modalities like computed tomography (CT) scans, it has been shown to be prone to error depending on patient alignment with the scanner's longitudinal axis. In this technique article, we describe a method using multiplanar reformatting on 2‐dimensional CT scans to create an altered coordinate system to measure TT‐TG measurements more accurately and efficiently. This method can drastically impact the accuracy and reproducibility of TT‐TG measurements for misaligned scans and can help ensure that patients are treated appropriately for their individual level of dysplasia.
- 22 May 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (10) , S256-S261.e3
No Improvement in Infection or Complication Rate With Extended Oral Antibiotic Prophylaxis After Primary Total Joint Arthroplasty
- 22 May 2026
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 41 (10) , S256-S261.e3
No Improvement in Infection or Complication Rate With Extended Oral Antibiotic Prophylaxis After Primary Total Joint Arthroplasty
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 19, 1-9
The Design and Development of a Novel Device that Converts a Patient-Controlled Intravenous Pump into an Oral Liquid Medication Dispenser for Non-Controlled Substances
Timely administration of oral medications is a significant inpatient challenge, particularly in the context of postoperative pain management with limited nursing resources. Delays in delivering non-opioid analgesics, such as acetaminophen, can result in poorly controlled pain and increased opioid use. To address this gap, we developed the Patient-Controlled Oral Liquid Dispenser (P-COLD), a novel bedside device that enables patients to self-administer non-controlled liquid medications within programmable safety parameters. The system integrates a hospital-grade intravenous patient-controlled analgesia (PCA) pump into a secure, 3D-printed housing that delivers precise doses of medication into a bedside cup upon patient request. The P-COLD was validated through laboratory testing and simulated-use evaluations without deployment in clinical patient care. Dose accuracy testing demonstrated consistent delivery within ±5% of target volume. Simulated usability testing with healthy volunteers confirmed reliable patient operation with minimal instruction. Nursing staff successfully completed training and setup protocols, and time-motion analyses indicated potential reductions in workflow interruptions and nursing burden during as-needed (PRN) medication delivery. The P-COLD was designed to enable patient-initiated delivery of non-controlled oral liquid medications without IV access and without requiring nurse presence at the bedside for each dose. Validation testing in the laboratory and through simulated use demonstrated accurate dosing, reliable usability, and favorable simulated workflow performance.
- 1 February 2026
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 19, 1-9
Open AccessThe Design and Development of a Novel Device that Converts a Patient-Controlled Intravenous Pump into an Oral Liquid Medication Dispenser for Non-Controlled Substances
Timely administration of oral medications is a significant inpatient challenge, particularly in the context of postoperative pain management with limited nursing resources. Delays in delivering non-opioid analgesics, such as acetaminophen, can result in poorly controlled pain and increased opioid use. To address this gap, we developed the Patient-Controlled Oral Liquid Dispenser (P-COLD), a novel bedside device that enables patients to self-administer non-controlled liquid medications within programmable safety parameters. The system integrates a hospital-grade intravenous patient-controlled analgesia (PCA) pump into a secure, 3D-printed housing that delivers precise doses of medication into a bedside cup upon patient request. The P-COLD was validated through laboratory testing and simulated-use evaluations without deployment in clinical patient care. Dose accuracy testing demonstrated consistent delivery within ±5% of target volume. Simulated usability testing with healthy volunteers confirmed reliable patient operation with minimal instruction. Nursing staff successfully completed training and setup protocols, and time-motion analyses indicated potential reductions in workflow interruptions and nursing burden during as-needed (PRN) medication delivery. The P-COLD was designed to enable patient-initiated delivery of non-controlled oral liquid medications without IV access and without requiring nurse presence at the bedside for each dose. Validation testing in the laboratory and through simulated use demonstrated accurate dosing, reliable usability, and favorable simulated workflow performance.